Loading...
•
Mar 31, 2025
Sage Q1 2025 Earnings Report
Reported first quarter 2025 financial results and provided pipeline and business updates.
Key Takeaways
Sage Therapeutics reported a significant decrease in net loss and operating costs for the first quarter of 2025 compared to the same period in 2024, driven by cost savings measures. Collaboration revenue from ZURZUVAE saw substantial growth, while ZULRESSO revenue was nil. The company maintains a strong cash position expected to fund operations into mid-2027.
Collaboration revenue from ZURZUVAE was $13.8 million in Q1 2025, a significant increase from $6.2 million in Q1 2024.
Net loss for Q1 2025 was $62.2 million, a substantial improvement from a net loss of $108.5 million in Q1 2024.
Research and development expenses decreased significantly in Q1 2025 due to cost savings and reprioritization of programs.
Cash, cash equivalents, and marketable securities stood at $424 million as of March 31, 2025, with a cash runway expected to mid-2027.
Revenue by Segment
Forward Guidance
Sage Therapeutics anticipates that its current cash reserves and anticipated funding will support operations until mid-2027. Overall operating expenses are expected to decrease significantly in 2025 compared to 2024, despite increased investment in ZURZUVAE commercialization.
Positive Outlook
- Existing cash, cash equivalents, and marketable securities are expected to support operations to mid-2027.
- Anticipated funding from ongoing collaborations.
- Estimated revenues are expected to contribute to the cash runway.
- Overall operating expenses are anticipated to substantially decrease in 2025 relative to 2024.
- ZURZUVAE joint commercialization investment will increase in 2025 to support growth.
Challenges Ahead
- Guidance excludes any potential milestone payments from collaboration agreements.
- The strategic alternatives review process remains ongoing with no set timetable.
- Future steps for SAGE-324 are still under evaluation.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...